Podcasts about biotech

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

In this podcast, Edmund Shing (Global Chief Investment Officer) dicusses how investors' over-optimism has begun to cool, leading to a shift toward others sectors.Following the strong momentum led by technology stocks in the US and in Asia, concerns rose over the elevated valuations that tech stocks had reached.Over the last week, a mini correction was seen, sending among others bitcoin down by 29% and tech giant Oracle by 34% from its September highs. This setback of global and US stocks should not worry investors as the Nasdaq 100 index has merely returned to the level it had reached in early October.However, while more speculative names and the tech sector stumble, other sectors are taking over leadership of the global stock market. Pharmaceutical & biotech sectors are lately outperforming the Nasdaq Index. Another more surprising outperforming industry in November is Oil & Gas.We maintain our positive 12-month view on global stocks and would suggest that now is a good time to look at sectors and stocks displaying relative strength outside of technology.Hosted by Ausha. See ausha.co/privacy-policy for more information.

An early rally in stocks gave way to a rough sell-off on Wall Street. How Nvidia's reversal, and a delayed jobs report gave way to a market meltdown, and how Walmart became a bright spot in the down day. Plus, Biotech more than doubling the performance of the broader market, as M&A action lights up the space. Where our next guest sees the most opportunity in the space, and if the biotech boom can continue into year end.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Synopsis: In a conversation rich with strategic insight, Coya Therapeutics CEO Arun Swaminathan unpacks the intersections of scientific innovation, business development discipline, and capital-efficient execution that define today's most resilient biotechs. With a 25-year foundation spanning R&D, clinical pharmacology, marketing, and BD, Arun offers investors a rare systems-level lens on how neurodegenerative programs progress from hypothesis to value inflection. Through his dialogue with host Alok Tayi, he breaks down Coya's differentiated Treg-modulating platform and the data emerging across ALS, FTD, and Alzheimer's. He explains why Coya's dual-mechanism approach—restoring regulatory T-cell function while reshaping the neuroinflammatory environment—is uniquely poised to change patient trajectories. Arun also delves into the structural logic behind Coya's partnership with Dr. Reddy's, demonstrating how complementary strengths in manufacturing, commercialization, and regulatory strategy can dramatically shift both timelines and capital needs. For investors tracking macro trends, he contextualizes shifting interest rates, pipeline gaps, and rising M&A momentum—and why 2026 may mark the beginning of a healthier biotech cycle. A must-listen for anyone evaluating platform durability, risk mitigation strategies, and next-generation neurodegenerative therapeutics. Biography: Arun Swaminathan, Ph.D., has over 20 years of hands-on healthcare business executive experience with an emphasis on corporate and business development, strategy, and finance. He possesses a demonstrated history of prospecting, evaluating, structuring, and closing company validating transactions that augment both organizational and shareholder value. Prior to joining Coya, Arun served as Chief Business Officer (CBO) for Actinium Pharmaceuticals (NYSE: ATNM) where he was responsible for all business development. Within 1 year of joining Actinium, he successfully moved forward negotiations to closure and executed a $452M deal with $35M upfront. Prior to Actinium, he was the CBO at Alteogen (196170.KQ) where he spearheaded over $6B in deals, including deals with two of the top 10 global pharma companies and a $1B+ deal within the first year of assuming the role of CBO. Prior to this, he co-founded and served as CEO of Lynkogen Inc, a pre-clinical stage biotech. Arun began his career in clinical development and commercial roles of increasing responsibility at BristolMyers Squibb and Covance. He obtained his Ph.D. in pharmaceutical sciences from the University of Pittsburgh.

In this episode of Data in Biotech, host Ross Katz sits down with John Liberty, Senior Bioanalysis Technical Sales Consultant at Thermo Fisher Scientific. They dive deep into how Watson LIMS™ supports regulated bioanalysis workflows, the evolving role of lab automation, and how Connect Enterprise aims to unify biotech digital ecosystems. What you'll learn in this episode: >> Why Watson LIMS is purpose-built for bioanalysis and how it enhances compliance and data traceability. >> The role of lab automation in boosting productivity and reducing manual tasks. >> How Connect Enterprise integrates lab systems across vendors into a seamless workflow.  >> Key considerations for implementing LIMS in startup versus established biotech environments. >> The ROI of digital lab solutions in supporting scalable, compliant biotech operations. Meet Our Guests John Liberty is a GMP-trained scientist with a strong focus on ELISA method development, validation, and transfer. He pairs his hands-on scientific background with experience in project management, CRO coordination, data analysis, and training, making him someone who really understands how work moves from the lab bench to real-world application. John has also spent time on the product and customer side, doing technical sales and demos for Watson LIMS™ software, giving him a rare blend of technical depth and communication skills. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with John Liberty  on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

InflaRx CEO Dr. Niels Riedmann joins Rx for Biotech to discuss how the company is pioneering complement-directed therapies to control severe inflammation and autoimmune disease. We break down the science behind INF904, and why C5a is such a powerful immune driver, and how precision immunology is shaping the next wave of treatment innovation.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate tapestry of scientific advancements, regulatory decisions, and strategic maneuvers shaping our industry.One of the notable stories involves Agios Pharmaceuticals, which is pushing forward with its sickle cell disease treatment, Pyrukynd, for FDA approval. This comes despite mixed results from their Phase 3 clinical trials, which led to a significant drop in their stock value. This scenario underscores the complexities of navigating clinical trial outcomes while pursuing breakthroughs in treating challenging diseases like sickle cell.Arrowhead Pharmaceuticals has marked a significant milestone with the FDA's approval of Plozasiran. This achievement not only marks Arrowhead's entry into the commercial sector but also highlights the competitive dynamics within biotech, as companies like Ionis Pharmaceuticals vie for market dominance with innovative therapies. Further strengthening its position, Arrowhead also received FDA approval for Redemplo, a siRNA-based therapeutic for rare genetic metabolic disorders. Despite facing volatility due to safety concerns in its partnership with Sarepta Therapeutics, this approval underscores RNA interference therapies' potential in precision medicine.In corporate strategy news, Alkermes is making moves to acquire Avadel Pharmaceuticals, offering up to $2.37 billion and overshadowing a competing bid from Lundbeck. Such acquisitions are part of a broader trend of consolidation in the industry aimed at expanding portfolios and market reach. Avadel's decision to accept Alkermes' revised offer over Lundbeck's bid highlights ongoing consolidation trends as companies expand their portfolios in competitive markets like narcolepsy drugs.On the investment front, Celltrion has committed $478 million to upgrade a U.S. manufacturing facility acquired from Eli Lilly. This expansion is crucial for increasing manufacturing capabilities within the biosimilars sector, where demand for cost-effective therapeutics is on the rise. Additionally, Celltrion's exploration beyond biosimilars with a potential $350 million deal involving Trioar's antibody platform demonstrates ambition to diversify its portfolio towards innovative biologics.Teva Pharmaceuticals is fostering innovation by inviting startups to tackle key challenges within biopharma through a global platform. This initiative reflects a growing trend toward open innovation and collaboration, seeking novel solutions to complex issues across research and development and manufacturing efficiencies.In regulatory news, the controversial $7.4 billion settlement plan involving the Sackler family and Purdue Pharma has received approval from a bankruptcy judge. This paves the way for Purdue's transformation into Knoa Pharma and highlights ongoing legal and ethical reckonings related to opioid liabilities within the industry.Cytokinetics remains committed to its independent path as it awaits FDA approval for its cardiovascular drug Aficamtem. The company's determination to commercialize without big pharma support reflects a trend where smaller biotech firms strive for autonomy while bringing first-in-class drugs to market.On an infectious disease front, Merck has demonstrated significant progress with its HIV treatment Islatravir in Phase 3 trials. This places Islatravir as a potential competitor against Gilead's Biktarvy, showcasing ongoing innovation within antiviral drug development.Additionally, Dexcom has gained clearance for its type 2 diabetes software integrating continuous glucose monitoring technology. This advancement exemplifies how digital health technologies are transforming chronic disease management bySupport the show

A inteligência artificial já faz parte da rotina de milhões de pessoas, acompanhando decisões, oferecendo respostas rápidas e até ocupando espaços antes reservados ao diálogo humano. Mas até que ponto essa tecnologia ajuda, atrapalha ou cria ilusões sobre o que sentimos e pensamos? No novo episódio do podcast de Biotech and Health, Camila Pepe e Carolina Abelin recebem a psicóloga Julia Catharino para analisar a influência da IA no comportamento e na saúde mental.Durante a conversa, Julia explica que a IA opera muito bem no campo objetivo, lógico e concreto, mas não alcança as nuances emocionais e simbólicas que definem a experiência humana. Ela alerta para o risco de buscarmos na tecnologia respostas imediatas para questões internas complexas, que exigem reflexão, elaboração e presença humana para serem compreendidas.Para pensar no futuro, a psicóloga reforça que a relação saudável entre humanos e máquinas dependerá menos da evolução tecnológica e mais da maturidade emocional de quem usa essas ferramentas. Discernimento, autoconhecimento e senso crítico serão essenciais para evitar que a IA se torne um espelho que apenas confirma certezas e desconecta pessoas de si mesmas.

There has been a lot of talk about "p(doom)"over the last few years. This has always rubbed me the wrong waybecause "p(doom)" didn't feel like it mapped to any specific belief in my head.In private conversations I'd sometimes give my p(doom) as 12%, with the caveatthat "doom" seemed nebulous and conflated between several different concepts.At some point it was decideda p(doom) over 10% makes you a "doomer" because it means what actions you should take with respect toAI are overdetermined. I did not and do not feel that is true. But any time Ifelt prompted to explain my position I'd find I could explain a little bit ofthis or that, but not really convey the whole thing. As it turns out doom hasa lot of parts, and every part is entangled with every other part so no matterwhich part you explain you always feel like you're leaving the crucial parts out. Doom ismore like an onion than asingle event, a distribution over AI outcomes people frequentlyrespond to with the force of the fear of death. Some of these outcomes are lessthan death and some [...] ---Outline:(03:46) 1. Existential Ennui(06:40) 2. Not Getting Immortalist Luxury Gay Space Communism(13:55) 3. Human Stock Expended As Cannon Fodder Faster Than Replacement(19:37) 4. Wiped Out By AI Successor Species(27:57) 5. The Paperclipper(42:56) Would AI Successors Be Conscious Beings?(44:58) Would AI Successors Care About Each Other?(49:51) Would AI Successors Want To Have Fun?(51:11) VNM Utility And Human Values(55:57) Would AI successors get bored?(01:00:16) Would AI Successors Avoid Wireheading?(01:06:07) Would AI Successors Do Continual Active Learning?(01:06:35) Would AI Successors Have The Subjective Experience of Will?(01:12:00) Multiply(01:15:07) 6. Recipes For Ruin(01:18:02) Radiological and Nuclear(01:19:19) Cybersecurity(01:23:00) Biotech and Nanotech(01:26:35) 7. Large-Finite Damnation --- First published: November 17th, 2025 Source: https://www.lesswrong.com/posts/apHWSGDiydv3ivmg6/varieties-of-doom --- Narrated by TYPE III AUDIO. ---Images from the article:

Get the Side Hustle Ideas Database [free]: https://clickhubspot.com/ckf Episode 765: Sam Parr ( ⁠https://x.com/theSamParr⁠ ) and Shaan Puri ( ⁠https://x.com/ShaanVP⁠ ) talk about every business Shaan tried before he made his first million. — Show Notes: (0:00) #1 Chipotle of Sushi (5:00) #2 Selling Wristbands Online (9:34) #3 Biotech with a billionaire (12:54) #4 Making the next billion dollar app (17:30) #5 Ride a wave (22:37) Shaan applies to Stripe (25:29) Going from 0/12 to 5/5 (26:35) Project selection (40:00) Your last dollar (46:00) Uncle Shaan's advice for 20 year olds (52:12) New segment: Life happens — Check Out Shaan's Stuff: • Shaan's weekly email - https://www.shaanpuri.com  • Visit https://www.somewhere.com/mfm to hire worldwide talent like Shaan and get $500 off for being an MFM listener. Hire developers, assistants, marketing pros, sales teams and more for 80% less than US equivalents. • Mercury - Need a bank for your company? Go check out Mercury (mercury.com). Shaan uses it for all of his companies! Mercury is a financial technology company, not an FDIC-insured bank. Banking services provided by Choice Financial Group, Column, N.A., and Evolve Bank & Trust, Members FDIC — Check Out Sam's Stuff: • Hampton - https://www.joinhampton.com/ • Ideation Bootcamp - https://www.ideationbootcamp.co/ • Copy That - https://copythat.com • Hampton Wealth Survey - https://joinhampton.com/wealth • Sam's List - http://samslist.co/ My First Million is a HubSpot Original Podcast // Brought to you by HubSpot Media // Production by Arie Desormeaux // Editing by Ezra Bakker Trupiano //

Join us for an insightful episode of The Edge of Show, where we dive deep as part of a media partnership into the world of decentralized identity, AI, and the future of digital trust with Billy Luedtke, the founder of Intuition Protocol. Billy shares his journey from angel investing to creating a decentralized trust layer for the Internet, reimagining identity, reputation, and verifiable information in the age of AI.In this episode, we explore:The intersection of decentralized identity and AIThe inspiration behind launching Intuition ProtocolHow decentralized identity can reshape our online interactionsThe concept of the "agentic internet" and its implications for our digital livesThe importance of verifiable data and decentralized reputation systemsThe future of knowledge sharing and the role of AI in our decision-making processesBilly also discusses the challenges of competing with big tech and the potential for a more decentralized and user-centric internet. Whether you're a tech enthusiast, a Web3 pioneer, or just curious about the future of digital identity, this episode is packed with bold ideas and real-world impact.Don't forget to subscribe, rate, and share this episode with friends who are excited about the future of technology and culture!Resources Intuition Website: https://www.intuition.systems/ Twitte/X: https://x.com/0xintuition Connect with Billy LuedtkeLinkedIn: https://www.linkedin.com/in/william-luedtke-b0a3bb5a/ Twitter: https://x.com/0xbilly Support us through our Sponsors! ☕

Are you tired of competition and struggling to find collaborators in biotech? In this episode, returning host Patrick Reed, RTTP, talks with Christiaan Engstrom, MBA, Founder and CEO of BLPN, a member-led club connecting life science dealmakers with one goal: helping each other succeed. Christiaan shares how BLPN has built a thriving community where collaboration, mentorship, and trust come first — creating opportunities that go far beyond business cards and conference booths. In this episode, you'll discover: How a simple mantra — “Find someone to help, repeat” — is reshaping biotech networking. Why connection, not competition, is the key to sustainable industry growth. How leaders can strengthen regional biotech ecosystems and bring coastal innovation energy inland. Tune in to learn how genuine collaboration can transform biotech partnerships – and why the most powerful deals start with helping someone else. Links: Connect with Christiaan Engstrom, MBA, and check out BLPN. Connect with Patrick Reed, RTTP, and learn about Auburn University IPX. Learn about Tulane Medicine Business Development and the School of Medicine. Connect with James Zanewicz, JD, LLM, RTTP, and Tamika Jackson. Check out JPM, BioAlabama, and The Beautiful Way Foundation. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

In this episode, we sit down with Dr. William Ho, President, CEO, and Co-Founder of IN8 Bio — a pioneering biotech company developing next-generation Gamma Delta T cell therapies for both solid and hematologic cancers.From Wall Street to the biotech lab, Dr. Ho shares his remarkable journey and how he's leveraging artificial intelligence, data analytics, and computational biology to reshape cell therapy development, manufacturing, and scalability.Discover how AI is transforming every stage of biotech — from drug discovery and clinical trial optimization to manufacturing automation and investor relations — and why Dr. Ho believes it's key to achieving IN8 Bio's mission of Cancer Zero.Key HighlightsFrom finance to pharma: How Dr. Ho's Wall Street experience shaped his approach to building a public biotech company.AI in biotech innovation: Real-world examples of using natural language processing and machine learning to uncover drug-development gaps.Data-driven discovery: How IN8 Bio uses AI, RNA Seq, and single-cell analysis to advance Gamma Delta T cell therapies.Smarter manufacturing: The role of AI and LLMs in optimizing cell-therapy production, reducing costs, and managing global supply chains.Regulatory readiness: How biotech companies can navigate FDA compliance while integrating AI tools.Capital markets & biotech: Why the next generation of investors discover biotech companies on TikTok — and how IN8 Bio adapts to the algorithmic market.Mission Cancer Zero: How AI will help achieve a future where no patient dies of cancer.About the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it's being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI's role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook |

Join host Justin Forman in Nairobi, Kenya, as he sits down with Jean-Paul Nageri, co-founder of KaFresh, for an extraordinary conversation about finding divine solutions hidden in plain sight. When Jean-Paul watched his father's banana harvest spoil while waiting for traders, he didn't just see a problem—he saw a calling. What followed was a journey of "God Engineering" that led to a breakthrough preserving produce 10x longer using only natural plant oils.This episode explores how entrepreneurs can look to creation itself for answers to massive problems, why cold storage isn't always the answer for Africa, and how one biotech solution is transforming food security for millions. From Genesis 1:29 inspiration to cutting-edge agricultural innovation, this conversation reveals how faith, science, and entrepreneurship combine to solve real-world challenges.Key Topics:How watching his father lose 50% of harvests to spoilage launched an entrepreneurial journeyThe "God Engineering" discovery: unlocking preservation secrets from orange peelsWhy expensive Western solutions (cold storage) don't work for African farmersKaFresh breakthrough: Extending tomato shelf life from 1 week to 3+ months at room temperatureThe $1 trillion problem: Sub-Saharan Africa loses 37% of food production to post-harvest spoilageFrom synthetic chemicals to natural plant oils: reversing the globalization of food preservationHow monks in 1800s monasteries pioneered natural food coating techniquesBuilding an agricultural biotech platform: From preservation to accelerated seed germinationMaking insects "invisible" to produce instead of killing them with pesticidesUganda's 2 million smallholder farmers and the mindset shift that changes everythingNotable Quotes:"I like to use the term God Engineering. He literally leaves clues, but you have to have that discernment to be able to see the clues." - Jean-Paul Nageri"Why me, why me, why not some other big company? But that's God's plan. He normally takes the underdogs." - Jean-Paul Nageri"Anything that is good for you should be easy to pronounce." - Jean-Paul Nageri

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if one decision could make or break your drug's success? Join Charles River's Sarah Gould as she unpacks the high-stakes, emotion-filled world of species selection—and why it's about so much more than science. Discover how this critical choice shapes safety, speeds development, and drives innovation in today's evolving research landscape.Show Notes Alternative Methods Advancement Project  | Charles River Animals in Research  | Charles River Research Models and Services | Charles River Research Animals Models | Charles River 

China is investing heavily in cutting-edge genetic experiments. It’s part of their quest to become a biotech superpower. On today’s Big Take Asia Podcast, host K. Oanh Ha, Bloomberg’s Karoline Kan and Oxford University geneticist Andy Greenfield discuss China’s pharmaceutical ambitions and the loose regulatory environment that allows the animal testing industry to thrive. Read more: China Pushes Boundaries With Animal Testing to Win Global Biotech RaceSee omnystudio.com/listener for privacy information.

We love to hear from our listeners. Send us a message. Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market. We discuss the implications of recent blockbuster acquisitions, strategies for managing the current funding environment for biotech, what to look for in the IPO market in the coming months, alternative financing opportunities, and what besides lower interest rates might bring generalist investors back into the sector. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

The best biotech and pharmaceutical innovations mean nothing if they can't be protected—and protected fast. Our next guest, Josh Goldberg, is solving this challenge as co-managing partner at Nath, Goldberg & Meyer, the #1 ranked patent law firm for biotech and pharmaceutical technologies. With nearly three decades of IP law experience and a unique background as a lab researcher, Josh brings an insider's understanding of how innovation actually happens. He's helped industry leaders like Amgen, Takeda, and GlaxoSmithKline turn breakthrough treatments into patent-protected portfolios—often in under a year instead of the typical four-year timeline. Driven by a passion for focus and strategic IP timing, Josh shares his pioneering approach to biotech and pharmaceutical patent prosecution. Join us to discover how smart IP strategy drives licensing power, regulatory success, and company valuation. Let's go!Episode Highlights:Focus drives success – Companies fail by trying to do everything at once; staying deliberate and focused is key to making real impactOne-year patent timelines vs. four years – Josh uses USPTO's Track 1 program to secure patents in record time, improving fundraising and M&A positioningClient-centered approach wins – Listening to unique client needs instead of one-size-fits-all strategies earned the firm its #1 rankingDiagnostic patents are back – New USPTO Director signals the patent office is "open for business" again after a decade of restrictionsScientist turned patent attorney – Josh's lab background gives him insider understanding of how innovation actually happensAbout our Guest: Joshua is the patent attorney innovation-driven pharmaceutical companies call when they need to turn complicated technologies into protected assets in record time.As co-managing partner at Nath, Goldberg & Meyer—the #1 ranked patent law firm for biotech and pharmaceutical technologies in both 2024 and 2025—Joshua leads IP efforts across industries like biotech, pharma, agriculture, renewable energy, and advanced materials. Whether it's a blockbuster acne treatment like DUAC, a vitamin D analog lotion like Sorilux, OTC solutions like Salonpas and Germagic, or a leading drug used to reduce stomach acid and treat conditions like GERD, ulcers, and heartburn—like Protonix—Joshua helps turn high-stakes R&D into patent-protected portfolios, often in under a year instead of the typical four-year timeline.Though his climate and agricultre IP expertise has made him famous as the “green patent guy,” Joshua moves between disciplines skillfully and has helped industry leaders like Amgen, Takeda, Guilford Pharmaceuticals, Mayne, and Stiefel Laboratories (which was acquired by GlaxoSmithKline) build pharma portfolios that hold up under investor, acquirer, and FDA scrutiny.His journey didn't begin in IP law, but in the lab, researching experimental pharmaceutical delivery systems. It gave him an edge most attorneys don't have: understanding how innovation actually happens, and how to protect it without slowing a business down. Links Supporting This Episode: Nath, Goldberg & Meyer Website: CLICK HEREJoshua Goldberg LinkedIn page: CLICK HERENath, Goldberg & Meyer LinkedIn: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page:...

We're living longer than ever, but are we staying healthy longer? In this season finale, we explore how genomics, phenomics, and lifestyle choices intertwine to shape not just how long we live, but how well we live. Guests Dr. Jennifer Lovejoy of Phenome Health and HudsonAlpha's Nick and Meagan Cochran share how research projects like HOPE-AD are using big data, wearable tech, and personalized multimodal interventions to redefine wellness and bring new hope to Alzheimer's disease prevention.To go behind the scenes and learn more about this episode, visit “From Lifespan to Healthspan: Rethinking Brain Wellness.” If you prefer to watch your podcasts, head over to Youtube. Thanks for listening! We're now on YouTube- follow us here. To receive episode updates and bonus material, subscribe to our mailing list here.

Want a legal career blending Intellectual Property (IP), Biotechnology, and Business? We sit down with Jenna Matheny (Vice-President & Managing Director at APIOiX) to break down the path to a high-impact career in medical innovation. This episode is essential listening for law students and those interested in patent law who also have a passion for science, revealing a world of opportunities beyond traditional law firm life.In this episode, we discuss:The Innovation Lifecycle: How lawyers are involved from invention disclosure and patent strategy to regulatory approval (FDA) and commercialization.The Business of IP: The critical, often-overlooked importance of contracting and compliance in developing and licensing medical technology.Finding Your Niche: Jenna's unique career path through university Tech Transfer offices, incubators, and accelerators—and how law students can get their foot in the door.Beyond Science: The growing field of social innovation and how non-science majors can find rewarding IP careers focused on copyright and trademark.Practical Law School Advice: Which broad-based courses (like securities and international tax) set you up for success, and the value of clinics and residencies.(00:00) - Introduction: Blending Law, Science, and Business in an IP Career (01:43) - Meet Jenna Matheny: Expert in Medical Technology IP and Tech Consulting (04:28) - Defining Biotech vs. MedTech: Law's Role in FDA Approval (05:42) - The Core Practice Areas: Patents, Contracting, and Regulatory Compliance (10:09) - Career Pivot: From Medicine Interest to Patent Attorney Path (11:32) - Tech Transfer Offices (TTOs): How Law Students Can Gain Experience (14:28) - Incubators & Accelerators: Consulting and Internship Roles for Attorneys (20:39) - Practical Advice: Essential Law School Courses (Securities, Tax) and Clinics (24:26) - Serendipity & Networking: How Connections Change the Course of a Legal Career (25:59) - Social Innovation: IP Opportunities without a Science Background (Copyright & Trademark) Click here to view the episode transcript.

In this episode of The Top Line, Fierce’s Chris Hayden speaks with Foresight Diagnostics co-founders Dr. Jake Chabon and Dr. Max Diehn about how their company is delivering the next generation of minimal residual disease (MRD) detection in cancer care. Born from research at Stanford University, Foresight’s PhasED-Seq technology delivers ultra-sensitive detection—down to parts per ten million—enabling clinicians to identify microscopic traces of cancer that traditional imaging misses. The discussion explores how Foresight’s MRD platform, CLARITY, can have the ability to support more confident decision-making, from determining curative success in early-stage cancers to guiding consolidation treatment in lymphoma. Chabon and Diehn highlight the company’s biopharma collaborations, clinical trial integration, and evidence-driven approach to guideline inclusion. They also look ahead to a future where MRD testing becomes central to oncology surveillance, accelerating therapy approvals and complementing genomic and digital pathology tools to advance precision medicine.See omnystudio.com/listener for privacy information.

Send us a textPodcast Guesting is your best way to get visibility, credibility, and trust by sharing how you add value to your clients.In this episode of Business Growth Talks, hosted by Mark Hayward, listeners are treated to the remarkable journey of Marco Benitez, CEO and co-founder of Rook. Marco shares his path from a Taekwondo champion to spearheading a successful startup in the digital health space. Reflecting on his journey and challenges, Marco provides insights into the synergies between the discipline of martial arts and the resilience required in entrepreneurship. This episode is a masterclass on navigating startup challenges, building strategic partnerships, and the future of personalized healthcare.Marco delves into the inception of Rook, sharing the pivotal moment when he left a secure job in corporate pharma to pursue his dream of building a startup. The conversation covers the hurdles of innovating within healthcare tech, securing investment, and the critical role of discipline in entrepreneurship. With Rook, Marco emphasizes the transformation of wearable device data into actionable insights, underscoring the importance of preventing ailments before they arise. This insightful dialogue is a blend of personal anecdotes and practical advice for aspiring entrepreneurs eager to impact the health tech industry.Key Takeaways:Synergy of Disciplines: The discipline and perseverance from Marco's martial arts background significantly influenced his approach to entrepreneurship.Navigating Initial Challenges: Finding the first client and cultivating trust was crucial to Rook's early success and customer engagement.Strategic Partnerships: Alliances with entities like InterSystems accelerated Rook's influence in the health tech industry.Investor Relationships: Building authentic relationships and aligning investors with the company's mission were essential for Rook's funding success.Importance of Prenvention: Personalized data and proactive healthcare approaches can reshape health industries, offering better outcomes for individuals and organizations alike.SPONSORPodcast Guesting is your best way to get visbility, credibility and trust by sharing how you add value to your clients. If you want to set up a call, go to the websitewww.podcastintroduction.comResources:Rook Website: Try rook IOMarco Benitez on LinkedIn: Marco Antonio BenitezListeners are encouraged to dive into the full episode for more enriching conversations and stay tuned to discover more transformative journeys in the world of business, innovation, and entrepreneursSupport the showIf you want to watch the full video of this episode go to:https://www.youtube.com/@markhayward-BizGrowthTalksDo you want to be a guest on multiple podcasts as a service go to:www.podcastintroduction.comFind more details about the podcast and my coaching business on:www.businessgrowthtalks.comFind me onLinkedIn - https://www.linkedin.com/in/mark-hayw...Tik Tok - https://www.tiktok.com/@mjh169183YouTube Shorts - https://www.youtube.com/@markhayward-BizGrowthTalks/shorts

“Written from the point of view of one character and then another scene from the another character. Now, we would never shift point of view within a scene, but each scene, each segment of the book is from a different point of view.” - Lawrence ConnollyIn this How To Write the Future episode, “Building Character-Driven Action Adventure Stories with Lawrence Connolly,” podcast host Beth Barany interviews author Lawrence Connolly, where they explore his upcoming exciting projects, including a feature film with his brother and his new novel. They also dive into using deep POV to create characters that are emotionally compelling to draw a reader into the author's world and share advice for writers working on film adaptations.ABOUT LAWRENCE C. CONNOLLYLawrence C. Connolly's books include the collections This Way to Egress, whose titular tale of psychological horror was adapted for the Mick Garris film Nightmare Cinema; and the Bram-Stoker-nominated Voices, which features Connolly's best stories from The Magazine of Fantasy & Science Fiction, Twilight Zone, Year's Best Horror, and other top magazines and anthologies of science fiction, fantasy, and horror. A third collection, Visions, was praised by Publishers Weekly for featuring an eclectic mix of “entertaining and satisfying” SF. His novels include the eco-thrillers Veins, Vipers, and Vortex. World Fantasy Award winner T. E. D. Klein called Veins “a crime thriller as intense and fast-moving as a Tarantino movie.” This fall, Caezik Science Fiction will release his new novel Minute-Men: Execute & Run, a globetrotting adventure that combines elements of military science fiction, gaming, and medical suspense in a thrilling reinvention of the superhero genre. He is collaborating with brother Christopher Connolly and Academy Award-winning producer Jonathan Sanger to develop a feature film based on Execute & Run. He is also the writer of Mystery Theatre, a podcast produced by Prime Stage Theatre, who premiered his adaptation of Frankenstein in 2022. His newset commission, a play based on the life and works of Edgar Allan Poe, opens in November 2025 at Pittsburgh's New Hazelett Theatre.More at MinuteMenNovel.com. Website: https://lawrencecconnolly.com/Facebook: https://www.facebook.com/lawrence.c.connolly.9Instagram: https://www.instagram.com/lawrence_c_connolly/SHOW PRODUCTION BY Beth BaranySHOW CO-PRODUCTION + NOTES by Kerry-Ann McDadeEDITORIAL SUPPORT by Iman Llompartc. 2025 BETH BARANYhttps://bethbarany.com/Questions? Comments? Send us a text!--- CONNECTContact BethLinkedInCREDITSEDITED WITH DESCRIPT (Affiliate link)MUSIC: Uppbeat.ioDISTRIBUTED BY BUZZSPROUT: https://www.buzzsprout.com/?referrer_id=1994465

On this episode Gil Bashe and Gregg Masters engage Dennis Purcell, founding partner of Aisling Capital and architect of the original H&Q Life Sciences Conference that became the go to industry standard J.P. Morgan Healthcare Investor Conference. Purcell reflects on four decades of biotech investing—from Genentech's 1980 IPO to today's GLP-1 metabolic revolution. He unpacks capital cycles, the role of purpose-based investors, and the moral call to redirect innovation toward chronic disease and global health equity. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Two venture capitalists dissect why biotech burns billions while China runs trials in weeks—and why the next Genentech won't look anything like the last one. Elliot Hershberg reveals the "three horsemen" strangling drug development as costs explode to $2.5 billion per approval, while Lada Nuzhna exposes how investigator-initiated trials in Shanghai are rewriting the competitive playbook faster than American founders can file INDs. When the infrastructure that built monoclonal antibodies becomes the commodity threatening to hollow out an entire industry, the only path forward demands inventing medicines that are literally impossible to make without tools that don't exist yet—and they're betting everything on which approach survives. Resources:Follow Jorge on X: https://x.com/JorgeCondeBioFollow Lada on X: https://x.com/ladanuzhnaFollow Elliot on X: https://x.com/ElliotHershbergFollow Erik on X: https://x.com/eriktorenberg Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends!Find a16z on X: https://x.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zListen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYXListen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711Follow our host: https://x.com/eriktorenbergPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.   Stay Updated:Find a16z on XFind a16z on LinkedInListen to the a16z Podcast on SpotifyListen to the a16z Podcast on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this week's Hot Topics we break down the biggest stories shaping crypto and finance, with special guest James Wo, Founder & CEO of DFG.From the Senate's long-awaited crypto market structure bill to the Trump administration's plan for crypto-backed mortgages, this episode explores how policy, innovation, and real-world adoption are converging fast. James also shares DFG's strategy for the next market cycle, including their Bitcoin reserve, investment outlook for 2026 IPOs, and the projects leading the charge in DeFi and tokenization.TakeawaysRegulation is finally catching up with innovation.Stablecoins and real-world assets are leading the next wave.Long-term conviction still defines the builders shaping Web3.Support us through our Sponsors! ☕

In this episode of Retire While You Work®, Carson and Myles sit down with Investment Director of Federated Hermes, Jordan Stuart, for a high-level breakdown of what's really moving the economy right now. From the rise of AI and power infrastructure to biotech innovation, small-cap opportunities, gold's momentum, and Mag 7 concentration—Jordan walks through the charts and trends shaping today's market landscape.Together, they explore how these forces may influence long-term investors, financial planning decisions, and the broader outlook for 2025.

Bringing new drugs to market is a costly, time-consuming endeavor. On top of that, most medicines fail at some point in the research and development phase. Sarah Guo is joined by Sajith Wickramasekara, co-founder and CEO of Benchling, a company that has not only become the central system of record for biotech R&D, but uses AI agents to assist scientists to help fix this broken system. Sajith details the roadblocks that impede drug development and approval, the “dot com” bust occurring in biotech, and how AI agents and simulation can help scientists experiment faster. Plus, they talk about China's competitive rise in the pharma space, and the unique challenges of building an interdisciplinary culture that merges the worlds of science and software.  Rebuild biotech for the AI era - Sajith Wickramasekara Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @sajithw | @benchling Chapters: 00:00 – Sajith Wickramasekara Introduction 00:38 – Origin and Mission of Benchling 02:08 – The Drug Development Process 03:49 – Current State of the Biotech industry  08:46 – AI's Role in Biotech 16:14 – Benchling AI and Its Impact 18:36 – The Future of AI in Biotech  26:28 – Debunking AI Drug Discovery Myths 28:50 – Data's Role in Biotech 29:35 – The Importance of Tools in Pharma 31:28 – AI's Impact on Scientific Research 34:55 – Building a Biotech Company 40:18 – Interdisciplinary Collaboration in Biotech  43:06 – Tech and Biotech: Learning from Each Other 48:16 – Conclusion

Today's South Korean biotechs have a risk-on mentality, a willingness to partner, and strategies focused on globalization. On a special edition of the BioCentury This Week podcast recorded at Venture Café Cambridge, BioCentury is joined by a quartet of investors and executives with deep knowledge of Korea's life sciences ecosystem to discuss Korea biotech's push to globalize and the opportunities in the country for Western companies. The four guests joining BioCentury were Aram Hong, CEO of Korean start-up Apollon; investors Spencer Nam and Debra Peattie; and Boehringer Ingelheim GmbH's Andy Whittle.The podcast was recorded Nov. 6 on stage at the Venture Café Cambridge during the K-Blockbuster Night hosted by KHIDI, the Korea Health Industry Development Institute. BioCentury analyses discussed during the podcast include one on Asian deals and another on the speed of clinical trials in China. BioCentury returns to Asia early next year for the 5th East-West Summit, March 9-11 in Seoul. This episode of the BioCentury This Week podcast is brought to you by KHIDI.View Full story: https://www.biocentury.com/article/657558#KoreaBiotech #Globalization #LifeSciences #BiotechEcosystem #PharmaDeals #ClinicalDevelopment #Innovation #BiotechLeadership00:01 - Sponsor Message: KHIDI05:08 - Asia Deals and Korea's Role09:12 - Boehringer's Perspective13:51 - Apollon's Journey17:24 - Building Relationships23:20 - Investors' View To submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Send us a textIn this episode, an experienced angel investor explains how she evaluates founders, the value of firsthand problem knowledge, and why the best investments balance limited downside with exponential upside.Learn her million-dollar lesson: success comes from focusing on asymmetry, people, and time.https://familyoffices.com/

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling updates that underscore the dynamic nature of our industry, marked by scientific breakthroughs, strategic shifts, regulatory advancements, and more.Starting with Pfizer's ambitious endeavors in oncology, the company has initiated Phase 3 trials for its bispecific antibody PF-08634404, targeting non-small cell lung cancer. This innovative approach aims to supersede Keytruda by simultaneously targeting the PD-1 and VEGF pathways, crucial in tumor growth and immune evasion. Pfizer is making substantial strides with its PD-1xVEGF bispecific antibodies by announcing seven near-term trials, including a pivotal phase 3 trial comparing this agent to Keytruda in non-small cell lung cancer. This underscores Pfizer's commitment to developing next-generation immunotherapies that could redefine cancer treatment paradigms by offering more targeted options. The implications are significant; by enhancing therapeutic efficacy through this dual-targeted strategy, Pfizer could set new standards in lung cancer treatment, potentially improving patient outcomes and redefining first-line therapies.Meanwhile, a strategic merger between Mallinckrodt and Endo has culminated in a $6.7 billion transaction, resulting in the rebranding of the combined entity as Keenova. This merger is particularly notable for its decision to spin off the Par Health generics business. Such a move indicates a focused shift towards specialty pharmaceuticals aimed at rare diseases—a trend increasingly seen across the industry as companies pivot towards niche markets with high unmet needs.In financing news, Vor Bio's successful $100 million public offering highlights growing investor confidence in companies addressing autoimmune diseases. This capital will likely accelerate Vor Bio's clinical-stage programs, potentially transforming patient care in this challenging therapeutic area through new and effective treatments.On the regulatory front, Glenmark's Ryaltris has secured approval from China's National Medical Products Administration for treating moderate to severe allergic rhinitis. This approval is pivotal as Glenmark expands its footprint in respiratory therapeutics with innovative small molecule therapies designed to alleviate allergy symptoms—a sign of their strategic growth within this domain.Recent clinical trial results also offer promising news. CeleCor Therapeutics' zalunfiban has shown Phase 3 success for segment elevation myocardial infarction, while UbiVac's DPV-001 has demonstrated improved survival rates in head and neck squamous cell carcinoma. Engene's Detalimogene voraplasmid exhibited a 63% response rate in bladder cancer patients unresponsive to BCG therapy. These findings reflect ongoing advances in targeted therapies and personalized medicine approaches that continue to reshape the oncology landscape.In policy changes, the UK government has unveiled a five-year roadmap aimed at replacing animal testing with AI and 3D tissue models. This initiative marks a pivotal shift towards more ethical and technologically advanced methods in drug development, potentially accelerating discovery processes while reducing reliance on animal models—a significant move that aligns with global trends towards more humane scientific practices.Meanwhile, Richard Pazdur's appointment as director of the FDA's Center for Drug Evaluation and Research signals strategic leadership changes amidst ongoing organizational investigations. His extensive experience in oncology is expected to guide regulatory oversight during this transformative period for the agency. Dr. Richard Pazdur's appointment as director of CDER representsSupport the show

A lean funding environment has changed how biotechs approach workforce organization and executive hiring. Searches are becoming more targeted and intentional, and accountability–both for employers and candidates–is high. In this episode of Denatured, Leslie Loveless of Slone Partners describes how biotechs should approach building their executive teams, working with boards and investors to make decisions that will enable growth. She also discusses how the search and hiring processes has changed for both employers and candidates.This episode is presented in partnership with Slone Partners. HostChantal Dresner, Vice President of Marketing, BioSpaceGuestLeslie Loveless, Co-CEO and Managing Partner, Slone PartnersDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

In this episode of The Edge of Show, host Josh Kriger sits down with William Fey, founder of Ammalgam, to explore how his team is merging lending and trading into one seamless DeFi experience. With a background in math, software engineering, and crypto markets, William shares the journey behind creating a Decentralized Lending Exchange (DeLEx) that's setting new standards for capital efficiency, accessibility, and user experience ahead of its mainnet launch on Sonic.Key TakeawaysA deep look at the evolution from DeFi Summer to the next wave of unified on-chain tradingHow security innovation and design simplicity drive mainstream adoptionWhy impermanent gain may become the new framework for liquidity provisionWhether you're a DeFi veteran or exploring the next generation of financial systems, this episode breaks down complex concepts into real-world impact — a must-listen for anyone following the future of decentralized finance.Support us through our Sponsors! ☕

In this episode of Medsider Radio, we sat down with Somer Baburek, CEO and co-founder of Hera Biotech. Hera is developing AI-driven tissue diagnostics for conditions that disproportionately affect women, including endometriosis and cervical cancer.Before launching Hera, Somer spent nearly a decade in venture capital, where she evaluated early-stage medtech startups and learned what separates the survivors from the rest.In this conversation, Somer explains how Hera designed global clinical pathways that balance cost and credibility, why boutique CROs can outperform big names, and how a pre-commercial startup completed three strategic acquisitions using equity and brand trust rather than cash.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Somer Baburek.

Ofer Haviv didn't take the usual route into Biotech. With a background in economics and finance, he began his career far from the lab - but a long-standing passion for biology brought him back to science in an unexpected way.  Now CEO of Evogene, Ofer shares how he moved from CFO to spinning out a company at the intersection of AI and biology, building platforms to discover small molecule therapeutics and agricultural innovations. He reflects on leading through uncertainty, what makes a strong Biotech culture, and why staying focused on real-world problems is essential to innovation.  Evogene's evolution is far from over, but Ofer's story offers a rare and thoughtful look into the blend of science, business and humanity that drives Biotech forward. 

Send us a textGood morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking changes and innovations reshaping the landscape of drug development, clinical trials, and regulatory affairs.In a major move, Pfizer has successfully outbid Novo Nordisk to acquire Metsera for $10 billion. This strategic acquisition aims to bolster Pfizer's presence in the obesity treatment market by leveraging Metsera's GLP-1 receptor agonist technology. This acquisition underscores the continuing trend of consolidation within the pharmaceutical industry, enhancing competitive market positioning and reflecting a broader quest for novel therapeutic solutions.Eli Lilly has entered into a $1.2 billion collaboration with Sangenebio to advance RNA interference (RNAi) therapeutics targeting metabolic diseases. This partnership marks a pivotal shift towards utilizing RNAi technology to silence disease-causing genes, representing significant progress in metabolic disease treatment. The focus on innovative delivery mechanisms and targeted interventions is critical for accelerating drug development and enhancing therapeutic efficacy.Onchilles Pharma's recent Series A1 funding round, securing $25 million, marks a notable advancement in oncology therapeutics. The company's focus on dual-action cancer biologics targeting the ELANE pathway offers promising insights into immune activation in solid tumors. This investment exemplifies the growing interest in biologic therapies that provide targeted cancer treatments, potentially leading to more effective options for patients.Regulatory advancements are also making headlines. Chongqing Precision Biotech has received approval for Pujiolunxi, a treatment for pediatric relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), broadening therapeutic options for this challenging pediatric condition. Furthermore, Alembic Pharmaceuticals' generic version of Dasatinib tablets has gained FDA approval for Philadelphia chromosome-positive chronic myeloid leukemia, increasing accessibility to treatment.Several promising clinical trial results have emerged recently. Summit Therapeutics and Akeso Biopharma's Ivonescimab showed a 26% overall survival benefit in phase 3 trials for non-small-cell lung cancer. The potential of bispecific antibodies in combination therapies is gaining attention for its efficacy in difficult-to-treat cancers. Additionally, Regeneron's Dupixent has achieved phase 3 success in treating allergic fungal rhinosinusitis, reinforcing its role as a versatile treatment option across various inflammatory diseases.Advancements in cardiovascular therapeutics also continue to unfold. Merck & Co.'s Enlicitide Decanoate demonstrated over 50% LDL cholesterol reduction in a phase 3 study focused on atherosclerotic cardiovascular disease through PCSK9 inhibition. AstraZeneca's Baxdrostat showed significant blood pressure reduction in trials targeting treatment-resistant hypertension, highlighting the potential impact of aldosterone synthase inhibitors on cardiovascular health.The investment landscape remains robust with substantial fundraising activities such as Elephas Biosciences' $40 million Series B-2 for commercializing their live tumor profiling platform and Iambic's over $100 million series focused on AI-driven drug discovery. These investments underscore the industry's commitment to integrating advanced technologies like AI and live tumor profiling to enhance precision medicine capabilities.FDA regulatory updates are pivotal as well, notably with the decision to lift warning labels from hormone replacement therapy (HRT) products following an expert review that found previous warnings were based on misinformation regaSupport the show

Today's guest is Chris Clark. Chris was a biotech PM for 10 years at RS Investments, managing $4.5 billion. In today's episode, Chris discusses the complexities of the biotech sector, which has suffered a dramatic drawdown the past few years. He begins by explaining how biotech works, why it's such a unique sector, and what has kept investors and companies frozen the past few years. He also explains the different perspectives of venture capitalists and public market investors, the current regulatory environment and how AI may reshape drug development. (0:00) Starts (1:20) Biotech industry overview (18:09) Can you be a quant in biotech? (25:09) Biotech market cap distribution and benchmark underweighting (34:47) Addressing biotech volatility, market outlook, and non-pro investing tips (47:02) Private vs. public biotech investments (1:01:32) Global biotech markets (China) (1:09:48) AI and regulatory impact on biotech (1:21:14) US healthcare spending (1:33:48) Chris' most memorable investment ----- Follow Meb on X, LinkedIn and YouTube For detailed show notes, click here To learn more about our funds and follow us, subscribe to our mailing list or visit us at cambriainvestments.com ----- Follow The Idea Farm: X | LinkedIn | Instagram | TikTok ----- Interested in sponsoring the show? Email us at Feedback@TheMebFaberShow.com ----- Past guests include Ed Thorp, Richard Thaler, Jeremy Grantham, Joel Greenblatt, Campbell Harvey, Ivy Zelman, Kathryn Kaminski, Jason Calacanis, Whitney Baker, Aswath Damodaran, Howard Marks, Tom Barton, and many more.  ----- Meb's invested in some awesome startups that have passed along discounts to our listeners. Check them out here!  ----- Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Learn more about your ad choices. Visit megaphone.fm/adchoices

Biotech sees a breakout, as the group keeps up with the Mag7 stocks this year. The names leading that charge, and the prognosis for the group heading into year end. Plus, An AI warning for the real estate sector. Why one industry giant is flagging potential job cuts, and the next move for the space as rates decline.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery. EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. Mardi describes how drug companies transition from an R&D focus to commercializing products, how to read IPO windows and manage expectations, pricing new drugs, and balancing commercial efforts with pipeline renewal and maintenance. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

(0:00) Intro(1:55) About the podcast sponsor: The American College of Governance Counsel(2:42) Start of interview(3:56) Sue's origin story(5:42) The Rise of Biotech and her Career Journey (BioRad, Dupont, Amersham and Affymetrix)(12:04) Transition to Venture Capital (Mohr Davidow Ventures, GE Ventures)(14:55) Evolution of Corporate Venture Capital (since ~2010) "They [now] represent about 28% of all VC dollars going into startups."(19:32) Her Board Membership Journey (since 2000, as a board member at Affymetrix where she was an executive)(21:12) The Impact of AI on Governance(21:53) Cultural Differences in Boardrooms between founders and investors: "if you do governance right, it should be an enabler, not a suffocator."(29:24) Navigating Geopolitical Risks. Example: Align Technology: We moved about 90% of our Russia based developers to Armenia.(33:01) Challenges in Life Sciences Funding(34:52) The AI Investment Boom(37:16) Activism's Influence on Corporate Boards. "They punish the lack of communication. They punish obscuring things."  Reference to E189 with Joele Frank and Anne Chapman.(42:36) The Evolution of Compensation Structures "I think one of the key topics around comp is aligning pay, performance, and purpose."(45:34) Other relevant board topics: human capital, innovation, data and board culture.(47:57) The Importance of Board Refreshment (digital and IA natives that can govern in the boardroom)(49:12) Books that have greatly influenced her life:Passages by Gael Sheehy (1976)Mountains Beyond Mountains by Tracy Kidder (2003)(52:00) "People that helped her along"(54:23) An unusual habit or an absurd thing that she loves. (54:59) The living person she most admires: Francis Collins.(56:39) Quotes that she thinks of often or lives her life by.Sue Siegel is a highly accomplished executive, investor, and board member who has been at the forefront of innovation across life sciences, healthcare, and technology for more than three decades. You can follow Evan on social media at:X: @evanepsteinLinkedIn: https://www.linkedin.com/in/epsteinevan/ Substack: https://evanepstein.substack.com/__To support this podcast you can join as a subscriber of the Boardroom Governance Newsletter at https://evanepstein.substack.com/__Music/Soundtrack (found via Free Music Archive): Seeing The Future by Dexter Britain is licensed under a Attribution-Noncommercial-Share Alike 3.0 United States License

Artificial intelligence's rapid rise is causing anxiety for many, as it is already transforming the way we live and work. The concern is particularly high among young generations, who are wondering how it will change the labor market in the coming decades. But parents are also seeing the dangers AI and chatbots can pose as their children become more familiar with the technology. Jamie Metzl, a technology futurist and author of "Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform Our Lives, Work, and World," recently spoke with FOX News Rundown's Lisa Brady to discuss AI and address some of the issues that make Americans nervous. Metzl delves into AI's evolution from its origins to today's consumer applications, and how future advancements may lead to job losses, reduced privacy, and even safety risks. He also talks about the good it can bring, especially in medicine. We often have to cut interviews short during the week, but we thought you might like to hear the full interview. Today on Fox News Rundown Extra, we will share our entire interview with AI expert Jamie Metzl. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome to this episode of Hot Topics on the Edge of Show! Join hosts January Jones and Josh Krieger as they dive into the latest trends and challenges in the world of cryptocurrency with special guest Jack Ding from DomiChainIn this episode, we discuss:The trillion-dollar crypto chasm and the recent market fluctuations, including a significant loss of over $1 trillion in the crypto market since October 10th.The launch of Solana ETFs, which have seen remarkable success despite the overall market downturn.The formation of the Ethereum Protocol Advocacy Alliance and its potential impact on crypto regulation in Washington.The critical security vulnerabilities facing the rapidly growing DeFi sector, highlighted by recent hacks and the need for robust cybersecurity measures.How DomiChain is addressing the blockchain trilemma of scalability, security, and decentralization, and their innovative approach to enhancing security through AI and Bitcoin integration.Tune in for insightful discussions and expert perspectives on the future of blockchain technology and the evolving landscape of cryptocurrency. Don't forget to subscribe and follow us on your favorite platforms to stay updated on all things crypto!Support us through our Sponsors! ☕

Democrats have scored major victories in key off-year elections, and democratic socialist candidate Zohran Mamdani's mayoral win in New York City could be shaking up the party's direction. Meanwhile, Republicans fell short in New Jersey and Virginia but are already looking ahead to the midterms. New York Republican Congressman Mike Lawler joins the Rundown to discuss what these results reveal about voter trends, how the GOP plans to regroup, plus the latest on the ongoing government shutdown as both parties face pressure to strike a deal. Artificial intelligence is rapidly transforming the way we live and work, sparking both excitement and concern about its impact on society, especially among younger generations growing up alongside it. Jamie Metzl, a technology futurist and author of "Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform Our Lives, Work, and World," delves into AI's evolution from its origins to today's consumer applications. He also addresses the anxiety AI generates regarding job losses, privacy, and safety. Plus, commentary from commentary from Will Cain, host of FOX News Channel's The Will Cain Show and host of Will Cain Country on FOX News Audio. Learn more about your ad choices. Visit podcastchoices.com/adchoices

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join us for an exciting episode of The Edge of Show, live from Token2049 in Singapore! In this episode, we dive deep into the evolving landscape of cryptocurrency and blockchain technology with Yat Siu, the chairman of Animoca Brands.We discuss the current regulatory climate and how it has opened new doors for tokenization, particularly in real-world assets (RWAs). We also explore the implications of hyperinflation in various countries and how cryptocurrencies serve as a hedge against economic instability.Later, we welcome Alok K Sinha, co-founder and chief ecosystem officer of Pazalabs, who shares the innovative work they are doing in real estate tokenization. Discover how they are revolutionizing the mortgage process and creating opportunities for global investors through blockchain technology.Finally, Keith Kim, COO of Nextbase, talks about the MapleStory Universe project and the integration of Web 3.0 elements into gaming. Learn about the potential of stablecoins in gaming and the shift towards mobile gaming experiences.Don't miss this insightful discussion on the future of finance, technology, and gaming!Support us through our Sponsors! ☕